Fig. 5. Administration of KAT II inhibitor at beginning of light phase reduces activity and temperature in ECon and EKyn offspring who exhibit sex differences in locomotor activity.

Male and female offspring were tested in the open field test during the light or dark phase: A distance traveled, B velocity, C percent of time spent in center, D percent of time spent in corners. Adult ECon and EKyn offspring were treated with vehicle or PF-04859989 (30 mg/kg) at Zeitgeber time (ZT) 0. E 1-h bins of relative cage activity, sexes combined (three-way ANOVA: treatment × ZT interaction F_{(23, 487)} = 1.825, P < 0.05). F 6-h bins of relative cage activity in ECon, sexes combined (treatment × ZT interaction F_{(3, 39)} = 5.621, P < 0.01). G 6-h bins of relative cage activity in EKyn, sexes combined (treatment × ZT interaction F_{(3, 43)} = 3.175, P < 0.05). H 1-h bins of core body temperature, sexes combined (three-way ANOVA: treatment effect F_{(1, 29)} = 9.403, P < 0.01, treatment × ZT interaction F_{(23, 480)} = 2.978, P < 0.0001). I 6-h bins of core body temperature in ECon, sexes combined (treatment effect F_{(1, 14)} = 7.810, P < 0.05). J 6-h bins of core body temperature in EKyn, sexes combined (treatment effect F_{(1, 15)} = 7.507, P < 0.05, treatment × ZT interaction F_{(3, 43)} = 6.280, P < 0.01). Data are mean ± SEM. Percent change from vehicle treatment calculations are shown by arrows. Three-way ANOVA: ^#P < 0.05, ^##P < 0.01, ^####P < 0.0001. Two-way RM ANOVA: ^{^}P < 0.05, ^{^^}P < 0.01 with Fisher’s LSD post hoc test: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. N = 11–16 per group.